Scilex Holding Company to Showcase Innovations in Pain Management
Palo Alto, California - Scilex Holding Company (NASDAQ: SCLX) is thrilled to announce its participation in the upcoming 2024 Annual PAINWeek Conference. This exciting event will take place over three days in the lively city of Las Vegas, highlighting the latest advancements in pain management strategies. Scilex is committed to creating innovative non-opioid treatments for both acute and chronic pain, making this conference a perfect opportunity to share valuable insights and findings.
Focus on ZTlido (Lidocaine Topical System)
A major highlight of the conference will be ZTlido, a lidocaine topical system specifically formulated to provide relief for neuropathic pain, such as that associated with postherpetic neuralgia. Attendees can expect both oral and poster presentations that will enhance the conversation around non-opioid pain management solutions.
Key Dates for the Conference
Participants can anticipate several engaging presentations scheduled throughout the conference:
- On September 4, Dr. Charles Argoff, a highly regarded expert in pain management, will lead a non-CME presentation discussing alternatives to gabapentinoids for patients who have not found sufficient relief.
- The next day, September 5, will feature two significant poster presentations by Dr. Srinivas Nalamachu, focusing on the analysis of opioid use and the cost-effectiveness of the lidocaine topical system compared to traditional treatments.
Pioneering Non-Opioid Pain Management Solutions
Scilex Holding Company’s dedication to advancing non-opioid pain management is evident through its innovative product offerings. Alongside ZTlido, the company provides ELYXYB, an FDA-approved oral solution for treating acute migraines, and Gloperba, a unique liquid formulation designed to prevent gout flares.
Navigating the Pain Relief Landscape
As concerns over opioid prescription rates continue to rise, Scilex is strategically positioned to address a crucial need in pain management therapy. The widespread prevalence of chronic pain conditions underscores the urgent demand for effective, non-addictive alternatives, which is exactly where Scilex aims to make a significant impact.
Company Mission and Vision
Based in Palo Alto, Scilex Holding Company is at the forefront of developing and commercializing therapies that enhance patient outcomes in pain management. The company’s commitment to research and innovation is reflected in its diverse portfolio of products. By focusing on conditions with substantial unmet needs, Scilex is well-positioned to capture a significant share of the growing market for non-opioid therapies.
Contact Information
For further inquiries, Scilex encourages interested parties to reach out through the following channels:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
To learn more about Scilex Holding Company and its innovative products, visit www.scilexholding.com.
Frequently Asked Questions
What is ZTlido and how does it work?
ZTlido (lidocaine topical system) is a prescription product designed to relieve neuropathic pain associated with postherpetic neuralgia by delivering lidocaine directly to the affected area.
When is Scilex presenting at the PAINWeek Conference?
Scilex will present several key discussions and posters during the conference, specifically on September 4 and 5, showcasing the benefits of ZTlido.
Who is Dr. Charles Argoff?
Dr. Charles Argoff is a renowned expert in pain management, serving as the speaker for the highlighted presentation on the challenges associated with gabapentinoids.
What other products does Scilex offer?
In addition to ZTlido, Scilex offers ELYXYB for migraines and Gloperba for gout flare prevention, addressing various pain management needs.
How can I contact Scilex for more information?
You can reach Scilex Holding Company via email at info@scilexholding.com or through their website at www.scilexholding.com.
